Biological Properties of the Pathogen
Clostridium difficile is a large Gram-positive bacillus. The bacterium is motile due to numerous peritrichous flagella distributed across its surface. Under conditions unfavorable for the vegetative form, it produces oval subterminal spores. These spores exhibit exceptional resilience: in the environment (soil, water, or animal feces), they remain viable for 110 to 180 days and easily withstand high concentrations of antibiotics within the intestine.
Metabolically, the microbe is an obligate anaerobe, meaning oxygen is lethal to it. In laboratory culture, the bacterium grows well on blood agar. Its biochemical activity is relatively low. Metabolism relies on the fermentation of carbohydrates and proteins, yielding various fatty acids (acetic, butyric, isobutyric, isocaproic, and isovaleric acids) as end products.
Pathogenic Factors and Pathogenesis
The pathogenicity of C. difficile is entirely attributed to its ability to release dangerous exotoxins into the intestinal lumen. Two key toxins play the primary role:
- Toxin A (enterotoxin): stimulates massive fluid secretion into the intestinal lumen, leading to profuse diarrhea.
- Toxin B (cytotoxin): directly disrupts enterocyte cell membranes and inhibits intracellular protein synthesis, causing tissue necrosis.
The precipitating factor for infection is almost always the administration of antibacterial drugs. These drugs eradicate the beneficial obligate microflora that normally restrain pathogen growth. Having gained an open ecological niche, opportunistic C. difficile begins to proliferate rapidly and secrete toxins. As a result, specific plaques composed of mucus, fibrin, and cellular debris—known as pseudomembranes—form on the damaged mucosa of the large intestine.
Epidemiology and Clinical Presentation
The pathogen is classified as an opportunistic bacterium. In approximately 2–5% of completely healthy individuals, C. difficile coexists peacefully in the gut as transient flora (asymptomatic carriage). Transmission occurs via the fecal-oral route. The primary sources of infection are symptomatic patients or asymptomatic carriers.
The disease presents as an acute infection—enteric clostridiosis. The classic clinical presentation includes a triad of symptoms:
- Marked toxicosis (malaise, fever).
- Acute diarrheal syndrome (frequent, watery stools).
- Development of pseudomembranous colitis with spasmodic abdominal pain.
Note: Beyond intestinal disease, this clostridial species can occasionally participate in suppurative inflammatory processes and even gas gangrene.
Microbiological Diagnosis and Treatment
The primary clinical specimen for investigation is patient stool. Laboratories utilize three main groups of methods:
- Immunochemical (ELISA): allows direct detection of toxins A and B in stool. This is a critical step because the mere presence of the bacterium without toxin production does not confirm disease.
- Bacteriological: inoculation of material onto selective media to isolate a pure culture. Once grown, the strain must be tested for toxigenicity.
- Molecular-genetic: PCR for the rapid detection of specific pathogen DNA sequences.
Etiotropic therapy requires the immediate discontinuation of the offending antibiotic that triggered the dysbiosis, along with targeted agents against clostridia, such as vancomycin or metronidazole. Probiotics have also demonstrated efficacy as adjunctive therapy. Because no specific vaccination exists against this infection, rational antibiotic stewardship and strict hospital hygiene protocols remain paramount.